Long QT syndrome type 2 (LQT2) is caused by mutations in the gene KCNH2, encoding the hERG ion channel. Clinically, mild and severe phenotypes are associated with this cardiac channelopathy, complicating efforts to predict patient risk. The location of the mutation within KCNH2 contributes to this variable disease manifestation. Here we determined whether such phenotypic differences could be detected in cardiomyocytes derived from isogenic human induced pluripotent stem cells (hiPSCs) genetically edited to harbour a range of KCNH2 mutations.
Introduction
Congenital long QT syndrome (LQTS) is a genetic disease with an estimated prevalence of ~1:2000 individuals. It is characterised by a prolonged QT interval on an electrocardiogram that can lead to sudden cardiac death, particularly in young people 1, 2 . Although the identification of genes associated with LQTS has dramatically improved our understanding of the disease 3 , clinical management remains complicated by the variability in disease expressivity and penetrance among mutation carriers which range from lifelong asymptomatic to experiencing life-threatening arrhythmias 4 . While environmental factors are contributors to this clinical heterogeneity 5 , genetics also plays a major role through both the primary genetic mutation and the presence of additional genetic variants that modify the disease outcome 6, 7 .
Type 2 LQTS (LQT2) is the second most prevalent form of congenital LQTS and is due to mutations in KCNH2, which encodes the α subunit of the Kv11.1 (hERG) channel responsible for conducting the rapid delayed rectifier potassium current (I Kr ) in cardiomyocytes 8 .
Several studies have demonstrated that the location of the mutation within this ion channel is an important determinant of arrhythmic risk in LQT2 patients, with patients harbouring mutations in the pore-loop region at higher risk of cardiac events than those with mutations located in other regions [9] [10] [11] [12] . Furthermore, mutations that result in a dominant negative effect, in which the function of wildtype hERG is reduced or eliminated, also produce higher adverse event rates 12, 13 . However mutations identified within the pore-loop region can, in some instances, result in a less severe outcome 14 , highlighting the need for in vitro models to accurately classify these rare variants and for gaining mechanistic insights into their contribution to disease phenotypes.
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Cardiomyocytes derived from human induced pluripotent stem cells (hiPSCs) are now wellestablished as models for LQT2 [15] [16] [17] [18] . Indeed, a number of hiPSC lines have been derived from both symptomatic and asymptomatic patients with mutations in various regions of hERG 19 . However, as these lines are from different individuals, they harbour additional genetic variants that may functionally influence the disease phenotype observed and limit the utility of hiPSC-derived cardiomyocytes (hiPSC-CMs) for broad intragenotype risk stratification.
To create a tailored model to study the genetic aetiology of LQT2, we generated a set of isogenic hiPSC lines that possess heterozygous mutations within the pore-loop domain (KCNH2-A561T) or in the cytoplasmic tail (KCNH2-N996I) of hERG by genetically modifying a control hiPSC line. Molecular and functional comparisons of these edited lines confirmed not only that the KCNH2 variant hiPSC-CMs phenocopied the key features of LQT2 but also that differences due to the mutation were reflected in the cell lines. This included dissimilarities in the mechanism underlying the hERG channel trafficking defect caused by these mutations, as well as a more prolonged repolarisation observed in hiPSC-CMs with the pore mutation when measured as a paced syncytium. Furthermore, when these hiPSC-CMs were exposed to E-4031, a hERG channel blocker, they were more susceptible to proarrhythmic effects compared to either the hiPSC-CMs with the tail mutation or the unedited control. Our findings demonstrate the potential of hiPSC-CMs to reveal the inherent severity of individual KCNH2 mutations when using genetically-matched lines but also further advances hiPSC-CMs as a robust model for not only predicting risk but also in the development of better risk stratification for patients. 
Methods
An extended methods section is provided in the Supplementary material.
Genome editing
The KCNH2 variants (c.G1681A and c.A2987T) were introduced into a hiPSC control (KCNH2 WT/WT ; LUMC0020iCTRL-06) 20 line by CRISPR/Cas9-mediated gene editing.
Heterozygosity of clones was confirmed by Sanger sequencing. Sequences of the guide RNAs (gRNAs), single-strand oligonucleotides (ssODNs), PCR primers and the resulting hiPSC lines used in this study are listed in Supplementary material tables S1-S3.
Differentiation to hiPSC-CM
The hiPSC lines were differentiated into cardiomyocytes as described in the Supplementary material. All analyses were performed on cryopreserved hiPSC-CMs 5-9 days after thawing.
Electrophysiology
Voltage-clamp recordings of I Kr were made using pipette and bath solutions as previously described 17 . Action potentials (APs) of the hiPSC-CMs were recorded by perforated patchclamp and the dynamic clamp technique with injection of an inward rectifier potassium current (I K1 ) used to achieve a close-to-physiological resting membrane potential (RMP) 21 .
For electrophysiological analysis on multi-electrode arrays (MEAs), the field potential (FP) was recorded as previously described 22 . Sequential addition of increasing concentrations of E-4031, a specific I Kr blocker, was performed with recordings initiated following 1 min of incubation.
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Optical recordings
The hiPSC-CMs were labelled with organic fluorescent dyes and the resulting signals recorded and analysed as described in the Supplementary material.
Statistical Analysis
Results are presented as mean ± SEM, with comparison between groups performed using one-way or two-way ANOVA followed by Tukey's multiple comparisons test for post hoc analysis. Pairwise comparisons were additionally performed using the Student's t-test following one-way ANOVA if one of the null hypotheses could be rejected 23 . Curve fitting from regression models and statistical analyses were performed with Graphpad Prism 8 software, with a P value <0.05 considered statistically significant. 9
Results
Generation and characterisation of an isogenic set of KCNH2 variant hiPSC lines
A limitation of hiPSC lines derived from unrelated patients with different LQT2-causing mutations is the inability to compare the resulting hiPSC-CMs under genetically-matched conditions. Therefore, to detect phenotypic differences arising from the region in which the mutation was located in KCNH2, we elected to genetically introduce these mutations into a well-characterised hiPSC line derived from a healthy individual (KCNH2 WT/WT ) 20 .
Furthermore, we confirmed that this cell line did not carry any known disease-causing mutations by performing whole exome sequencing and examining a panel of 107 genes known to be linked to inherited arrhythmia syndromes or cardiomyopathies 24 ( Supplementary Table S4 ). All coding sequence variants identified were predicted to be benign due to their frequency in the general population being ≥1%. The only exception was a rare variant identified in DOLK, the gene encoding dolichol kinase. Homozygous mutations in this gene can lead to multi-systemic glycosylation disorders including dilated cardiomyopathy, with individuals typically not surviving to adulthood 25 . However, the variant identified in the KCNH2 WT/WT line is unlikely to be pathogenic as the hiPSCs were derived from a healthy 51-year old female and were heterozygous for the DOLK variant.
We then used a CRISPR/Cas9-mediated gene editing strategy to generate an isogenic set of hiPSC lines harbouring a missense variant either within the pore-loop domain (Figure 1 ). RFLP analysis identified clones that appeared to be genetically modified (Supplementary Figure S1 ) and these were subsequently confirmed by Sanger sequencing to be either heterozygous for the KCNH2-A561T (KCNH2 PR/WT ; Figure 1E ) or the KCNH2-N996I (KCNH2 TL/WT ; Figure 1F ) variant.
For each mutation, a second independent isogenic heterozygous clone (KCNH2 PR/WT cl2 and KCNH2 TL/WT cl2) was also selected for further characterisation (Supplementary Figure S2 and S3). All clones were assessed by Sanger sequencing for potential off-target modifications due to the CRISPR/Cas9 transfection, with no insertions or deletions detected at any of the genomic loci examined ( Supplementary Table S5 ). Furthermore, G-band karyotyping of these clones indicated the lines were karyotypically normal, and the undifferentiated hPSCs expressed the stem cell markers SOX2, OCT-4, SSEA4, NANOG (Supplementary Figure S2 -S4).
Mutations in distinct regions of hERG cause differing trafficking defect phenotypes
A monolayer-based differentiation protocol was used to differentiate the KCNH2 variant and KCNH2 WT/WT hiPSC lines to cardiomyocytes. Flow cytometric analysis for the pancardiomyocyte marker cardiac troponin T (cTnT) indicated that all lines, except KCNH2 PR/WT cl2, differentiated with similar efficiencies, with on average ~70-80% of the cells being cTnT + ( Figure 2A Figure S5 ). For functional comparisons between the cell lines it is important that the cardiomyocyte population contains a similar proportion of ventricular cells. The hiPSC-CMs (cTnT + cells) were therefore further characterised for the expression of the ventricular cardiomyocyte marker, MLC2v. On average, the proportion of hiPSC-CMs that were ventricular was between 45-64%, including for the KCNH2 PR/WT cl2 line, (Figure 2A Figure S5 ). The hiPSC-CMs also displayed characteristic sarcomeric structures that were positive for -actinin and myosin heavy chain ( Figure 2C ). Both KCNH2 PR/WT and KCNH2 TL/WT hiPSC-CMs expressed equal fractions of mutant and wildtype KCNH2 transcripts ( Figure 2D ), confirming that the introduced mutations did not disrupt biallelic expression of the gene and suggesting that any differences observed between the cell lines would be due to dysfunction of hERG. Western blot analysis for hERG identified two protein bands -the fully glycosylated mature form (155 kDa) and the coreglycosylated precursor form (135 kDa). While in KCNH2 WT/WT hiPSC-CMs the mature form was predominantly present, in both KCNH2 PR/WT and KCNH2 TL/WT hiPSC-CMs higher expression of the precursor form was detected ( Figure 2E ), indicating that both mutations lead to a defect in trafficking of hERG to the cell membrane.
Finally, we determined how the trafficking defects caused by both KCNH2 mutations affected I Kr . Representative examples of current traces in individual hiPSC-CMs from both KCNH2 variant and KCNH2 WT/WT hiPSC-CMs are shown in Figure 2F , with I Kr measured as an E-4031-sensitive current. The I Kr tail density was significantly reduced in both KCNH2 PR/WT and KCNH2 TL/WT hiPSC-CMs compared to the KCNH2 WT/WT hiPSC-CMs ( Figure 2G ). For example, after a voltage step to +10 mV, the I Kr tail density was decreased by 51% in the KCNH2 TL/WT hiPSC-CMs and by 73% in the KCNH2 PR/WT hiPSC-CMs. Taken together, these findings suggest that although both KCNH2 variants result in a trafficking defect of hERG, the KCNH2 TL/WT variant leads to haploinsufficiency while the KCNH2 PR/WT variant causes a dominant-negative phenotype.
The dominant-negative KCNH2 mutation causes a more severe electrical phenotype
To determine whether the differences in I Kr density between the two KCNH2 variants was also reflected in the AP duration (APD), APs from individual hiPSC-CMs were recorded ( Figure 3A) . The APD at 50% and 90% repolarisation (APD 50 and APD 90 , respectively) were significantly prolonged for both KCNH2 variant lines (KCNH2 PR/WT : 185±17ms (APD 50 ), 243±19ms (APD 90 ); KCNH2 TL/WT : 198±16ms (APD 50 ), 254±18ms (APD 90 )) compared to the KCNH2 WT/WT hiPSC-CMs (131±11ms (APD 50 ), 151±11ms (APD 90 )), however there was no significant difference between the two KCNH2 variant lines ( Figure 3B ). At both slower and faster pacing frequencies (0.2-4Hz), the differences in APD 90 between the KCNH2 variant and wildtype lines remained, with no difference between the KCNH2 PR/WT and KCNH2 TL/WT hiPSC-CMs (Supplementary Figure S6) . Additionally, arrhythmogenic activity as evidenced by the presence of early after depolarisations (EADs), during 0.2 Hz stimulation was detected in both KCNH2 variant lines but not the KCNH2 WT/WT line ( Figure 3C and D). Also here, there was no difference in the frequency of EADs between the two lines (KCNH2 PR/WT : 18.2%; KCNH2 TL/WT : 17.6%). No significant differences in AP amplitude (APA) and RMP were observed between any of the lines, and while upstroke velocity (V max ) appeared faster in the KCNH2 PR/WT hiPSC-CMs, this was not significant (P=0.07) ( Figure 3B ).
Next, we investigated whether differences could be detected between the KCNH2 PR/WT and KCNH2 TL/WT hiPSC-CMs if measured in a syncytium. Figure 3E shows representative FP recordings of the hiPSC-CMs obtained from a MEA platform. Differences in beating frequency were observed between the 3 lines, with the KCNH2 PR/WT hiPSC-CMs showing a significantly faster beat period than the control KCNH2 WT/WT hiPSC-CMs (1920±123ms vs 3117±338ms). Therefore, the FPD was corrected (cFPD) for beat rate variability according to Bazett's formula ( Figure 3F ). Mirroring the APD differences observed in single hiPSC-CMs, the cFPD was significantly prolonged in KCNH2 PR/WT and KCNH2 TL/WT hiPSC-CMs (605±70ms and 499±40ms, respectively) compared to KCNH2 WT/WT hiPSC-CMs (245±15ms), but was not significantly different between the two KCNH2 variant lines. The second KCNH2 PR/WT and KCNH2 TL/WT clones corroborated these findings with similar beat period and cFPD values (Supplementary Figure S7 ). Collectively, these data indicate that the genetically engineered KCNH2 PR/WT and KCNH2 TL/WT hiPSC-CMs displayed the expected electrophysiological characteristics of the LQT2 phenotype, however no differences in baseline measurements or frequency of arrhythmic events were found between the hiPSC-CMs harbouring these mutations.
Finally, we also evaluated the KCNH2 variant lines using a high-speed optical system that can simultaneously measure the AP, intracellular Ca 2+ transients and contraction-relaxation kinetics of hiPSC-CM monolayers under paced conditions 26 . This enables the rapid assessment of how LQT2-causing mutations affect the complete excitation-contraction coupling cascade. Representative transients of the three measured parameters for each of the lines are shown in Figure 3G . Analysis of the voltage traces also showed a significant increase in APD 90 for both the KCNH2 PR/WT and KCNH2 TL/WT hiPSC-CMs (403±35ms and 350±21ms, respectively) compared to the KCNH2 WT/WT hiPSC-CMs (297±33.5ms; Figure 3H ).
Both Ca 2+ transient and contraction at 90% duration (CaD 90 and ContD 90 respectively) were also significantly prolonged in the KCNH2 variant lines compared to the wildtype hiPSC-CMs (KCNH2 WT/WT : 570±8ms (CaD 90 ), 429±18ms (ContD 90 ); KCNH2 PR/WT : 620±10ms (CaD 90 ), 492±23ms (ContD 90 ); KCNH2 TL/WT : 610±9ms (CaD 90 ), 456±6ms (ContD 90 )). Importantly, the APD 90 and ContD 90 of the KCNH2 PR/WT hiPSC-CMs were significantly prolonged compared to the KCNH2 TL/WT hiPSC-CMs. Although the CaD 90 also appeared prolonged, this did not reach significance (P=0.05). This demonstrates that, under carefully controlled recording conditions, differences in I Kr density are also reflected in the electrophysiological phenotype of the hiPSC-CMs, with the dominant negative-causing KCNH2 mutation leading to a more pronounced increase in APD than the haploinsufficiencycausing KCNH2 mutation. Furthermore, these differences are also reflected in both intracellular Ca 2+ transients and contraction-relaxation kinetics, suggesting that these parameters are also differentially influenced by mild and severe LQT2-causing mutations.
KCNH2 PR/WT and KCNH2 TL/WT hiPSC-CMs exhibit differing sensitivities to E-4031
To determine if the electrophysiological differences observed between the three lines also led to differing responses to known arrhythmogenic compounds, we examined the response of the hiPSC-CMs to E-4031 ( Figure 4 ). Figure 4A shows representative FP recordings in the presence of increasing concentrations of E-4031, with arrhythmic events such as EADs or fibrillations, detected in all three lines. As spontaneous beating ceased in some recordings when the cells were exposed to >300 nM E-4031 (Supplementary Figure S8) , analysis of the effect of E-4031 on FPD prolongation was performed up to this concentration. The FPD of KCNH2 PR/WT and KCNH2 TL/WT hiPSC-CMs was significantly prolonged compared to KCNH2 WT/WT hiPSC-CMs at >1 nM E-4031 ( Figure 4B ). When FPD was normalised to baseline measurements, the change in FPD at 300 nM, was significantly different for the KCNH2 PR/WT hiPSC-CMs compared to other two lines ( Figure 4C ), indicating the KCNH2 PR/WT hiPSC-CMs were more sensitive to I Kr blockade. Although the beat period between cell lines varied, it was unaffected for both the KCNH2 TL/WT and KCNH2 WT/WT hiPSC-CMs at <10 µM E-4031 (Supplementary Figure S9A) . The cFPD was also examined, with differences between the KCNH2 PR/WT hiPSC-CMs and the other two lines still discernible (Supplementary Figure S9B The second KCNH2 PR/WT and KCNH2 TL/WT clones also showed similar differences in sensitivity to E-4031 following FPD normalisation, with analysis performed to 100 nM E-4031 due to some KCNH2 PR/WT hiPSC-CMs becoming quiescent at 300 nM ( Supplementary Figure S8 ; Figure S10A and B). Analysis of cFPD showed a similar trend although it was not significant (Supplementary Figure S10C, D) , possibly due to overcompensation of the FPD-beat rate dependence for the KCNH2 TL/WT cl2 hiPSC-CMs ( Supplementary Figure S10E-G) . Overall, the multiple analyses we have performed with two separate clones for each mutation clearly demonstrate that the KCNH2-A561T mutation results in hiPSC-CMs that are more sensitive to I Kr blockade than the KCNH2-N996I mutation.
To determine if these E-4031-induced differences in FPD between the lines also led to changes in the frequency of arrhythmia-like events, we examined the FP recordings for the occurrence of abnormal repolarisations, fibrillation, and quiescence. Persistent E-4031induced arrhythmic events were first detected in the KCNH2 PR/WT , KCNH2 TL/WT and KCNH2 WT/WT hiPSC-CMs at 100nM, 300nM and 1 µM respectively (Supplementary Figure S8) .
We also quantified the proportion of recordings that exhibited these arrhythmic responses with increasing concentrations of E-4031 ( Figure 4A and D) . Here too the KCNH2 PR/WT hiPSC-CMs were the most predisposed with 100% of recordings showing such events at ≥3 µM E-4031, followed by the KCNH2 TL/WT hiPSC-CMs with >80% of recordings becoming arrhythmic; while <55% of KCNH2 WT/WT hiPSC-CMs recordings showed such a response even at the highest E-4031 concentration (300µM). The E-4031 concentration that resulted in 50% of the maximal response was also significantly different between the lines (KCNH2 PR/WT : 298 nM; KCNH2 TL/WT : 536 nM; KCNH2 WT/WT : 2.98 µM; P<0.01). This increased susceptibility to E-4031-induced arrhythmia-like events in the KCNH2 PR/WT hiPSC-CMs was also observed in the second set of KCNH2 PR/WT and KCNH2 TL/WT clones examined (Supplementary Figure S11A ).
Finally, we investigated the possibility of developing a scoring system based on previously described methods 27, 28 to estimate the arrhythmogenic risk to E-4031 for the different 16 hiPSC-CM lines. We included variable beat period (score 1), which has previously been classified as a "mild" arrhythmia-type 27 as an additional category. Abnormal repolarisation was given a score of 2, while hiPSC-CMs that were fibrillating or became quiescent were scored 3 and 4 respectively. Both KCNH2 PR/WT and KCNH2 TL/WT hiPSC-CMs had higher arrhythmia risk scores compared to the KCNH2 WT/WT hiPSC-CMs at all concentrations of E-4031 analysed, with both lines significantly greater at 1 µM E-4031 and these differences remaining between the KCNH2 PR/WT and KCNH2 WT/WT hiPSC-CMs at higher concentrations ( Figure 4E) . Differences in the arrhythmia risk score were also observed between the second KCNH2 PR/WT and KCNH2 TL/WT clones (Supplementary Figure S11B ). Taken together these results demonstrate a difference in susceptibility to arrhythmias between the variant lines and the KCNH2 WT/WT hiPSC-CMs, with KCNH2 PR/WT hiPSC-CMs more sensitive to E-4031 than the KCNH2 TL/WT hiPSC-CMs.
Discussion
Next-generation sequencing has had a profound impact on clinical genetic testing for LQTS, leading to the rapid identification of disease-causing variants in patients 5 . However, interpreting the functional consequences of these variants is often inconclusive due to the variable expressivity and incomplete penetrance of these diseases 4 , as well as the unexpectedly high level of background genetic variation observed in LQTS-susceptibility genes 29 . This makes it challenging to not only accurately diagnose the patient, but also to determine appropriate clinical management. The ability to generate hiPSCs from patients, combined with advances in genome editing technologies, has demonstrated how such a platform can be used to determine the pathogenicity of variants of uncertain significance (VUS) 30, 31 , or the contribution of genetic modifiers to the disease phenotype 32 . However, the extent to which hiPSCs can reflect intragenotype differences in disease risk such as that observed between LQT2 patients has not been fully explored 33 . Here, we investigated this and demonstrate that genetically-matched hiPSC lines can model subtle differences in disease severity that are directly attributable to the KCNH2 mutation.
Most KCNH2 mutations in the cytoplasmic tail cause haploinsufficiency, with mutant subunits failing to co-assemble with wildtype subunits. This results in approximately half of the channels trafficking to the cell membrane and a ≤50% reduction in I Kr 34 . In contrast, KCNH2 mutations within the pore region typically have dominant-negative effects 13 , frequently causing abnormal trafficking of the entire channel to the cell membrane, and thereby resulting in even fewer functional channels and a >50% I Kr reduction 34, 35 .
Consequently, LQT2 patients with missense mutations in the pore-loop region are at greater risk of an arrhythmia-related cardiac event [9] [10] [11] [12] . In the hiPSC-CMs we detected a <50% I Kr decrease with the KCNH2-N996I mutation and a >70% reduction for the KCNH2-A561T mutation, indicating haploinsufficiency and dominant negative effects respectively, but also suggesting that tetrameric ion channels containing one KCNH2-A561T subunit can traffic to the cell membrane but have limited functionality. A previous study evaluating KCNH2-A561T in HEK293 cells was unable to detect any current 36 , but here only the mutant KCNH2-A561T subunit was overexpressed which could explain why no channels were able to traffic to the membrane. Our findings also support other studies using hiPSCs that found pharmacological correction of trafficking defects may be a valid therapeutic strategy for KCNH2 mutations located in the pore region 18, 37 .
We hypothesised that these differences in I Kr would also be reflected in the electrophysiological phenotype of the hiPSC-CMs. Although all three platforms used to assess the electrophysiology of the lines demonstrated a clear prolongation of the APD and FPD for both KCNH2 variant lines compared with the KCNH2 WT/WT hiPSC-CMs, it was only with optical recordings that the APD was observed to be significantly more prolonged in KCNH2 PR/WT than KCNH2 TL/WT hiPSC-CMs. These discrepancies in sensitivity are likely due to differences in the setup and cellular configuration between the experimental approaches.
Sparsely seeded hiPSC-CMs, such as those used for patch clamp recordings, show greater electrophysiological variability compared to measurements performed on confluent monolayers 38 , which could confound the detection of subtle electrophysiological differences. Indeed, when confluent monolayers of hiPSC-CMs were measured using either MEAs or optically, the KCNH2 PR/WT lines had longer field-and action potentials compared to the KCNH2 TL/WT hiPSC-CMs that were significantly different when the cells were paced.
We also evaluated the cytosolic Ca 2+ transients and contraction kinetics of all three lines, as these are also key parameters that can be altered in LQTS [39] [40] [41] [42] . As expected, both LQT2causing mutations resulted in a significant prolongation in Ca 2+ transients and contractionrelaxation duration when compared to KCNH2 WT/WT hiPSC-CMs. Interestingly, we also observed significant differences in contractility kinetics between the two KCNH2 variants.
Contraction duration differences are known to exist between symptomatic and asymptomatic LQTS patients 43 and this has been proposed as an additional parameter to measure alongside QT interval for improving risk stratification in LQTS patients 44 .
In LQT2 patients, sudden arousal is the most frequent trigger of an arrhythmic cardiac event 45 , and patients with mutations in the pore-loop region have a significantly increased risk 46 . This is also the case when the triggering factor is not arousal or exercise-related (e.g. fever, medication, sleep) 46 . To mimic the effect of such triggers, we examined the behaviour of the hiPSC-CMs when treated with the I Kr blocker, E-4031. We observed differing responses to the QT-prolonging drug between the three lines, with the KCNH2 PR/WT hiPSC-CMs exhibiting a larger response to I Kr blockade than the KCNH2 TL/WT hiPSC-CMs, which exhibited similar changes in normalised FPD as KCNH2 WT/WT hiPSC-CMs. These differences in sensitivity to I Kr block could be due to the dominant-negative effect of the KCNH2-PR mutation, additional gating kinetic defects in trafficked hERG channels that include the KCNH2-A561T subunit 47 , or a combination of both. The results also differ from those recently reported by Yoshinaga and colleagues who observed a smaller change in FPD in response to I Kr blockade in hiPSC-CMs derived from LQT2 patients than in control or mutation-corrected hiPSC-CMs 48 . However, this discordance could be mutation-specific as they also observed an increased susceptibility to arrhythmias with the LQT2 hiPSC-CMs.
Indeed, in line with their differing FPD response to I Kr blockade, the KCNH2 PR/WT hiPSC-CMs also exhibited an increased occurrence of arrhythmia events in the presence of E-4031.
Similarly, a greater proportion of measurements from KCNH2 TL/WT hiPSC-CMs displayed arrhythmic activity compared to KCNH2 WT/WT hiPSC-CMs. Akin to systems being established to evaluate the arrhythmogenic risk of pharmacological compounds 27 , a similar matrix could be developed to assess the risk of specific mutations in patients to different triggering conditions. As proof of concept, we determined the arrhythmia risk score for all three lines at various concentrations of E-4031, observing that the KCNH2 PR/WT hiPSC-CMs had a higher arrhythmogenic risk at 1 µM. It will be necessary to evaluate the accuracy and reliability of this scoring system with a larger panel of KCNH2 mutations as well as for different triggers, but this study demonstrates the sensitivity of this in vitro model for detecting these intragenotype-phenotype differences. Such an approach could have important clinical implications, for example by identifying particular KCNH2 mutations that predispose patients to increased arrhythmic risk and whom might benefit from more vigilant monitoring.
This study also highlights the benefit of introducing mutations into a well-characterised control hiPSC line. Indeed, this approach is the only option for identifying mutation-specific functional changes, as genetic background differences between patient-derived hiPSCs would likely mask these, even if the variant was corrected. This strategy also means that the mutations examined are not limited by the availability of patient material. While common variants present in the control hiPSC line might modify the disease phenotype, all mutations are evaluated on the same genetic background, thereby nullifying their effect. Furthermore, as similar responses were detected in both clonal lines generated for each mutation, the 21 differences observed between the experimental groups are unlikely to be due to variants that have arisen spontaneously in culture or from CRISPR/Cas9-induced off-target effects.
In conclusion, we have established that hiPSCs can determine the underlying severity of individual KCNH2 mutations, reflecting the mutation-location risk differences seen in LQT2 patients. This study demonstrates a new application in which hiPSC-CMs could contribute to improvements in the diagnosis, prognosis, and risk stratification of patients with congenital LQTS. 
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